Market Cap | 449.61M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -89.24M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 2.00% |
Sales | 15.03M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -27.00% |
Dividend | N/A | Price/Book | 2.19 | EPS next 5Y | - | 52W High Chg | -67.00% |
Recommedations | - | Quick Ratio | 5.46 | Shares Outstanding | 7.48B | 52W Low Chg | 27.00% |
Insider Own | 14.20% | ROA | -26.15% | Shares Float | 5.92B | Beta | 3.24 |
Inst Own | 5.98% | ROE | -44.37% | Shares Shorted/Prior | -/- | Price | 0.07 |
Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 120,250 | Target Price | - |
Oper. Margin | -880.15% | Earnings Date | Feb 28 | Volume | 69,110 | Change | -11.95% |
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.